130.88
price down icon0.65%   -0.85
pre-market  Pre-market:  131.17   0.29   +0.22%
loading
Merck & Co Inc stock is currently priced at $130.88, with a 24-hour trading volume of 5.29M. It has seen a -0.65% decreased in the last 24 hours and a +4.65% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $130.8 pivot point. If it approaches the $132.9 resistance level, significant changes may occur.
Previous Close:
$131.73
Open:
$131.37
24h Volume:
5.29M
Market Cap:
$331.49B
Revenue:
$61.40B
Net Income/Loss:
$2.31B
P/E Ratio:
72.71
EPS:
1.8
Net Cash Flow:
$11.04B
1W Performance:
+0.50%
1M Performance:
+4.65%
6M Performance:
+28.33%
1Y Performance:
+12.75%
1D Range:
Value
$130.79
$131.78
52W Range:
Value
$99.14
$133.10

Merck & Co Inc Stock (MRK) Company Profile

Name
Name
Merck & Co Inc
Name
Phone
908-740-4000
Name
Address
2000 Galloping Hill Road, Kenilworth, NJ
Name
Employee
69,000
Name
Twitter
@Merck
Name
Next Earnings Date
2024-06-03
Name
Latest SEC Filings
Name
MRK's Discussions on Twitter

Merck & Co Inc Stock (MRK) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-11-24 Downgrade Societe Generale Hold → Sell
Jan-04-24 Upgrade TD Cowen Market Perform → Outperform
Nov-09-23 Initiated Deutsche Bank Buy
Oct-27-23 Upgrade BMO Capital Markets Market Perform → Outperform
Oct-20-23 Upgrade UBS Neutral → Buy
Jul-14-23 Initiated HSBC Securities Hold
Apr-13-23 Upgrade Citigroup Neutral → Buy
Mar-28-23 Downgrade Societe Generale Buy → Hold
Mar-13-23 Downgrade Wells Fargo Overweight → Equal Weight
Mar-06-23 Initiated Jefferies Buy
Feb-22-23 Upgrade Wolfe Research Peer Perform → Outperform
Jan-04-23 Upgrade BofA Securities Neutral → Buy
Nov-18-22 Initiated Credit Suisse Outperform
Oct-10-22 Upgrade Guggenheim Neutral → Buy
Sep-14-22 Upgrade Berenberg Hold → Buy
Jul-06-22 Upgrade Daiwa Securities Neutral → Buy
Jun-06-22 Resumed SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Equal-Weight
Dec-17-21 Initiated Goldman Buy
Dec-16-21 Initiated Daiwa Securities Neutral
Dec-13-21 Downgrade UBS Buy → Neutral
Dec-09-21 Initiated Wells Fargo Overweight
Dec-07-21 Downgrade Guggenheim Buy → Neutral
Nov-29-21 Downgrade Citigroup Buy → Neutral
Nov-19-21 Initiated BMO Capital Markets Market Perform
Nov-01-21 Upgrade Argus Hold → Buy
Sep-07-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-27-21 Resumed Truist Buy
May-20-21 Downgrade Argus Buy → Hold
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Aug-03-20 Upgrade Goldman Neutral → Buy
Jun-12-20 Downgrade Wolfe Research Outperform → Peer Perform
Feb-27-20 Initiated Barclays Overweight
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Oct-17-19 Resumed BofA/Merrill Neutral
Aug-16-19 Initiated SVB Leerink Outperform
Jul-03-19 Initiated Mizuho Buy
May-28-19 Initiated Goldman Neutral
May-13-19 Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18 Reiterated Citigroup Buy
Oct-09-18 Resumed Guggenheim Buy
Apr-23-18 Upgrade Goldman Neutral → Buy
Apr-17-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18 Upgrade Barclays Equal Weight → Overweight
Mar-12-18 Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18 Reiterated Leerink Partners Mkt Perform
Feb-07-18 Reiterated Morgan Stanley Equal-Weight
Jan-16-18 Upgrade SunTrust Hold → Buy
View All

Merck & Co Inc Stock (MRK) Financials Data

Merck & Co Inc (MRK) Revenue 2024

MRK reported a revenue (TTM) of $61.40 billion for the quarter ending March 31, 2024, a +6.11% rise year-over-year.
loading

Merck & Co Inc (MRK) Net Income 2024

MRK net income (TTM) was $2.31 billion for the quarter ending March 31, 2024, a -82.30% decrease year-over-year.
loading

Merck & Co Inc (MRK) Cash Flow 2024

MRK recorded a free cash flow (TTM) of $11.04 billion for the quarter ending March 31, 2024, a -1.97% decrease year-over-year.
loading

Merck & Co Inc (MRK) Earnings per Share 2024

MRK earnings per share (TTM) was $0.90 for the quarter ending March 31, 2024, a -82.42% decline year-over-year.
loading

Merck & Co Inc Stock (MRK) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth
May 04 '24
Option Exercise
127.51
27,126
3,458,836
163,720
Oosthuizen Johannes Jacobus
President, U.S. Market
May 04 '24
Option Exercise
127.51
912
116,289
24,271
Klobuchar Michael A
EVP - Chief Strategy Officer
May 04 '24
Option Exercise
127.51
887
113,101
24,058
Smart Dalton
SVP Fin. - Global Controller
May 04 '24
Option Exercise
127.51
612
78,036
4,730
Smart Dalton
SVP Fin. - Global Controller
May 03 '24
Option Exercise
128.26
2,046
262,420
4,708
Romanelli Joseph
President, Human Health Int?l
May 02 '24
Option Exercise
128.80
2,262
291,346
21,831
Smart Dalton
SVP Fin. - Global Controller
May 02 '24
Option Exercise
128.80
381
49,073
3,048
Merck & Co., Inc.
10% Owner
Mar 11 '24
Buy
23.00
21,397,205
492,135,715
1,000
Davis Robert M
Chairman, CEO & President
Feb 14 '24
Option Exercise
73.73
85,021
6,268,598
433,348
Litchfield Caroline
EVP & CFO
Feb 14 '24
Option Exercise
58.08
38,291
2,223,941
89,199
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. Merck & Co., Inc. has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, Premier Inc., Cue Biopharma, Inc., Foundation Medicine, Inc., Daiichi Sankyo Company, Limited, and Cold Genesys, Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
drug_manufacturers_general JNJ
$154.28
price up icon 1.05%
$164.35
price up icon 0.34%
drug_manufacturers_general NVS
$102.69
price down icon 0.51%
$314.72
price down icon 1.35%
drug_manufacturers_general PFE
$28.92
price up icon 0.35%
Cap:     |  Volume (24h):